Law360, New York (June 18, 2009, 12:00 AM ET) -- Sandoz Inc., Mayne Pharma Inc., Teva Pharmaceutical Industries Ltd. and Hospira Inc. have won summary judgment in a dispute with Sanofi-Aventis US LLC, which accused the generics manufacturers of infringing two patents for the popular colon cancer drug Eloxatin.
Judge Joel Pisano of the U.S. District Court of New Jersey granted the generics makers’ motion for summary judgment Wednesday, finding that they used a different process than Sanofi to formulate optically pure oxaliplatin, marketed as Eloxatin.
Mayne also sought a motion for summary judgment of invalidity,...
Generics Triumph Over Sanofi In Cancer Drug Quarrel
To view the full article, take a free trial now.
